This drug is also undergoing phase II trial in combination with nivolumab, an anti‐PD‐1 monoclonal antibody in EGFR mutant/T790M+ NSCLC patients who have progressed on first‐line EGFR TKI (NCT02323126) (Table 1). Here, EGFR is linked to non-small cell lung carcinoma.